Clinical roundup: Data for Vertex, Sarepta, Lilly, Alligator, Corbus and Vera

New acute pain data are likely to support regulatory approval of Vertex’s non-opioid analgesic, but a miss on a secondary endpoint does raise questions about the extent to which payers will cover the therapy.

Tuesday’s readout showed that VX-548 from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) met the primary endpoints in two Phase III studies, significantly improving pain scores compared with placebo in patients who had undergone abdominoplasty or bunionectomy. The company is aiming to submit an NDA to FDA in mid-2024, with approval possible the following year...